Omeprazole/Clopidogrel

PreclinicalSmall molecule

UUniversity of Maryland, Baltimore

Omeprazole/Clopidogrel is one of 3 small molecule programs targeting Clopidogrel. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ClopidogrelCompleted

ClopidogrelPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Clopidogrel

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

82 2

St. John's Wort

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

1 3

Omeprazole/Clopidogrel

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clopidogrel1 trial

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01341600·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Omeprazole/Clopidogrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omeprazole/Clopidogrel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omeprazole/Clopidogrel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Maryland, Baltimore

Omeprazole/Clopidogrel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clopidogrel1 trial

References

Drug Info

Quick Facts

Related News